Floatz logo

Metformin

Microsatellite Instability-High Solid Malignant Tumor

Dan ZandbergSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Microsatellite Instability-High Solid Malignant Tumor cohort.

Asset / SponsorPhaseRating
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Pembrolizumab
Neonc Technologies, Inc.
Phase 2B
Letrozole
Dan Zandberg
Phase 2CCC
Rosiglitazone
Dan Zandberg
Phase 2CCC
Ipilimumab
Neonc Technologies, Inc.
Phase 1/2CC

View all 14 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →